40.27 USD
▼-0.20-0.49%
盘后 40.11 -0.40%
2026-09-15
市值
$1.92B
市盈率
—
EPS
-10.05
股息率
—
52 周区间
23.00 – 55.42
成交量
256.94K
Beta
—
目标价
61.20
52W 低 23.0052W 高 55.42
价格走势
公司简介
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovale...